Characterization and targeting of a novel pathway promoting Parkinson’s Disease

促进帕金森病的新途径的表征和靶向

基本信息

  • 批准号:
    10855706
  • 负责人:
  • 金额:
    $ 64.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-15 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT It is well established that many age-related neurodegenerative diseases are driven by the aggregation of improperly processed or misfolded proteins. For example, the aggregation of α-synuclein (α-Syn) within Lewy bodies results in a constellation of diseases referred to as synucleinopathies. These include Parkinson’s Disease (PD) and Parkinson’s Disease Dementia (PDD). The mechanisms leading to neuronal loss in PD and PDD remain unknown, however, neuroinflammation is thought to be a common feature, including microglial activation in the early stages of neurodegeneration, and evidence from both animal models and patient studies supports the involvement of the adaptive immune response and α-Syn reactive T cells. In this application we identify a previously unrecognized pathway promoting α-Syn-induced neuroinflammation and neurodegeneration. We show that this pathway is mediated by the protease, tissue plasminogen activator (tPA) through an interaction with the N-methyl-D-aspartate receptor-1 (NMDAR1). Using an AAV-α-Syn mouse model we find that tPA levels in the SN are significantly increased in mice overexpressing α-Syn, and that tPA deficiency protects dopaminergic neurons from degeneration and reverses behavioral deficits induced by α-Syn neurotoxicity. The action of tPA is independent of its proteolytic activity but can be prevented by treatment with Glunomab, a blocking antibody that binds the NMDAR1 and selectively inhibits its interaction with tPA. Both tPA deficiency and Glunomab treatment prevent neurodegeneration, normalize behavior, reduce microglia activation, and inhibit T-cell infiltration. Based on these preliminary data we will test the hypothesis that in response to neuronal overexpression or aggregation of α-Syn increased expression of tPA promotes neuroinflammation through interaction with the NMDAR1 and recruitment of cytotoxic lymphocytes resulting in neurodegeneration and leading to PD and PDD. We will test this hypothesis in two different synucleinopathy models, an AAV-α-Syn mouse model of PD, and an α-syn preformed fibril (α-syn PFF) model of PDD in mice.
项目摘要/摘要 众所周知,许多与年龄相关的神经退行性疾病是由聚集的 加工不当或错误折叠的蛋白质。例如,α-突触核蛋白(α-Syn)在刘易斯内的聚集 身体会导致一系列称为联核病的疾病。其中包括帕金森氏症 帕金森氏病(PD)和帕金森氏病痴呆(PDD)。帕金森病和PDD导致神经元丢失的机制 然而,目前尚不清楚,神经炎症被认为是一个共同的特征,包括小胶质细胞的激活。 在神经退化的早期阶段,来自动物模型和患者研究的证据支持 获得性免疫反应和α-Syn反应性T细胞的参与。在此应用程序中,我们标识了一个 以前未知的促进α-Syn诱导的神经炎症和神经变性的途径。我们 表明这一途径是由蛋白酶、组织型纤溶酶原激活物(TPA)通过相互作用而介导的 与N-甲基-D-天冬氨酸受体-1(NMDAR1)结合。使用aav-α-syn小鼠模型,我们发现tPA水平 在过度表达α-syn的小鼠的SN中显著增加,tPA缺乏保护 防止多巴胺能神经元变性和逆转α-Syn神经毒性所致的行为障碍。这个 TPA的作用独立于其蛋白水解性,但可被格伦单抗预防。 与NMDAR1结合并选择性地抑制其与tPA相互作用的封闭抗体。两种tPA缺乏症 和格伦单抗治疗可防止神经退行性变,使行为正常化,减少小胶质细胞的激活,并 抑制T细胞的侵袭。基于这些初步数据,我们将检验这一假设,即对神经元的反应 α-Syn过表达或聚集tPA表达增加通过以下途径促进神经炎症 与NMDAR1的相互作用和细胞毒性淋巴细胞的募集导致神经变性和 导致帕金森病和帕金森病。我们将在两个不同的联核病模型中检验这一假设,AAV-α-SYN 小鼠帕金森病模型和α-syn预成纤维(α-syn pff)模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel A Lawrence其他文献

Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages
纤溶酶原促进肉瘤生长并抑制肿瘤浸润巨噬细胞的积累
  • DOI:
    10.1038/sj.onc.1205951
  • 发表时间:
    2002-12-16
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Alejandro Curino;David J Mitola;Hannah Aaronson;Grainne A McMahon;Kamran Raja;Achsah D Keegan;Daniel A Lawrence;Thomas H Bugge
  • 通讯作者:
    Thomas H Bugge

Daniel A Lawrence的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel A Lawrence', 18)}}的其他基金

A Novel PAI-1 Function Drives Lung Fibrosis
PAI-1 的新功能可驱动肺纤维化
  • 批准号:
    10605479
  • 财政年份:
    2022
  • 资助金额:
    $ 64.71万
  • 项目类别:
The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease Neuropathology
PAI-1 在脑微血管功能障碍和阿尔茨海默病发展中的作用 神经病理学
  • 批准号:
    10314556
  • 财政年份:
    2021
  • 资助金额:
    $ 64.71万
  • 项目类别:
The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease Neuropathology
PAI-1 在脑微血管功能障碍和阿尔茨海默病发展中的作用 神经病理学
  • 批准号:
    10629303
  • 财政年份:
    2021
  • 资助金额:
    $ 64.71万
  • 项目类别:
Mechanism of thrombolytic tPA induced intracerebral hemorrhage after stroke
溶栓tPA致脑卒中后脑出血的机制
  • 批准号:
    8655918
  • 财政年份:
    2012
  • 资助金额:
    $ 64.71万
  • 项目类别:
Mechanism of thrombolytic tPA induced intracerebral hemorrhage after stroke
溶栓tPA致脑卒中后脑出血的机制
  • 批准号:
    8487469
  • 财政年份:
    2012
  • 资助金额:
    $ 64.71万
  • 项目类别:
Mechanism of thrombolytic tPA induced intracerebral hemorrhage after stroke
溶栓tPA致脑卒中后脑出血的机制
  • 批准号:
    8345099
  • 财政年份:
    2012
  • 资助金额:
    $ 64.71万
  • 项目类别:
Characterization of the role of PAI-1 in lipid metabolism
PAI-1 在脂质代谢中的作用表征
  • 批准号:
    8247042
  • 财政年份:
    2011
  • 资助金额:
    $ 64.71万
  • 项目类别:
Laboratory Testing Core
实验室测试核心
  • 批准号:
    8247047
  • 财政年份:
    2011
  • 资助金额:
    $ 64.71万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8247048
  • 财政年份:
    2011
  • 资助金额:
    $ 64.71万
  • 项目类别:
Laboratory Testing Core
实验室测试核心
  • 批准号:
    8150067
  • 财政年份:
    2010
  • 资助金额:
    $ 64.71万
  • 项目类别:

相似海外基金

AcT-Cog: Online cognitive assessment in the Alteplase compared to Tenecteplase (AcT) trial.
AcT-Cog:阿替普酶与替奈普酶 (AcT) 试验相比的在线认知评估。
  • 批准号:
    444794
  • 财政年份:
    2021
  • 资助金额:
    $ 64.71万
  • 项目类别:
    Operating Grants
INTERRAcT: Thrombus characteristics for predicting Reperfusion with Alteplase compared to Tenecteplase
INTERRAcT:与替奈普酶相比,阿替普酶预测再灌注的血栓特征
  • 批准号:
    433102
  • 财政年份:
    2020
  • 资助金额:
    $ 64.71万
  • 项目类别:
    Operating Grants
Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry based Pragmatic Randomized Controlled Trial
阿替普酶与替奈普酶治疗急性缺血性中风患者的比较:QuICR
  • 批准号:
    401715
  • 财政年份:
    2019
  • 资助金额:
    $ 64.71万
  • 项目类别:
    Operating Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
  • 批准号:
    nhmrc : 1079696
  • 财政年份:
    2015
  • 资助金额:
    $ 64.71万
  • 项目类别:
    Project Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
  • 批准号:
    nhmrc : GNT1079696
  • 财政年份:
    2015
  • 资助金额:
    $ 64.71万
  • 项目类别:
    Project Grants
Low-Dose Tenecteplase vs Standard-Dose Alteplase for Acute Ischaemic Stroke: An Imaging Based Safety and Efficacy Study
低剂量替奈普酶与标准剂量阿替普酶治疗急性缺血性中风:一项基于影像学的安全性和有效性研究
  • 批准号:
    nhmrc : 510722
  • 财政年份:
    2008
  • 资助金额:
    $ 64.71万
  • 项目类别:
    NHMRC Project Grants
Treament of Deep Vein Thrombosis with Alteplase
阿替普酶治疗深静脉血栓
  • 批准号:
    7004919
  • 财政年份:
  • 资助金额:
    $ 64.71万
  • 项目类别:
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
  • 批准号:
    8565339
  • 财政年份:
  • 资助金额:
    $ 64.71万
  • 项目类别:
Treament of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
  • 批准号:
    7593114
  • 财政年份:
  • 资助金额:
    $ 64.71万
  • 项目类别:
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
  • 批准号:
    8952839
  • 财政年份:
  • 资助金额:
    $ 64.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了